United Therapeutics Corporation $UTHR Shares Sold by Ruffer LLP

Key Points

• Ruffer LLP reduced its stake in United Therapeutics by 25.1%, selling 3,611 shares, and now holds 10,763 shares worth approximately $3.09 million.
• Multiple analysts have adjusted their price targets for United Therapeutics, with Jefferies raising it to $564.00, while JPMorgan lowered theirs to $330.00, reflecting a range of opinions on the stock's value.
• Insider trading saw Judy D. Olian and COO Michael Benkowitz sell a combined 24,300 shares of United Therapeutics, totaling over $10 million in transactions, indicating a significant reduction in their ownership percentages.

Ruffer LLP lowered its position in shares of United Therapeutics Corporation (NASDAQ:UTHR - Free Report) by 25.1% during the second quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 10,763 shares of the biotechnology company's stock after selling 3,611 shares during the quarter. Ruffer LLP's holdings in United Therapeutics were worth $3,093,000 as of its most recent filing with the SEC.

Other large investors also recently bought and sold shares of the company. SVB Wealth LLC purchased a new stake in United Therapeutics during the 1st quarter worth $32,000. Geneos Wealth Management Inc. grew its holdings in United Therapeutics by 141.7% during the 1st quarter. Geneos Wealth Management Inc. now owns 145 shares of the biotechnology company's stock worth $45,000 after acquiring an additional 85 shares in the last quarter. Sound Income Strategies LLC acquired a new position in United Therapeutics during the 1st quarter worth $49,000. Brooklyn Investment Group grew its holdings in United Therapeutics by 103.2% during the 1st quarter. Brooklyn Investment Group now owns 193 shares of the biotechnology company's stock worth $59,000 after acquiring an additional 98 shares in the last quarter. Finally, WPG Advisers LLC acquired a new position in United Therapeutics during the 1st quarter worth $60,000. Hedge funds and other institutional investors own 94.08% of the company's stock.

Analysts Set New Price Targets

UTHR has been the subject of several recent analyst reports. Jefferies Financial Group raised their price objective on shares of United Therapeutics from $432.00 to $564.00 and gave the stock a "buy" rating in a report on Tuesday, September 2nd. JPMorgan Chase & Co. decreased their price target on shares of United Therapeutics from $350.00 to $330.00 and set an "overweight" rating for the company in a report on Tuesday, July 8th. Morgan Stanley reduced their target price on shares of United Therapeutics from $348.00 to $328.00 and set an "equal weight" rating for the company in a research note on Thursday, July 10th. Bank of America boosted their price target on shares of United Therapeutics from $314.00 to $463.00 and gave the stock a "neutral" rating in a research report on Tuesday, September 2nd. Finally, HC Wainwright boosted their target price on shares of United Therapeutics from $400.00 to $500.00 and gave the stock a "buy" rating in a report on Friday, September 5th. Nine research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company. According to data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average target price of $438.85.

Insiders Place Their Bets

In other news, Director Judy D. Olian sold 1,800 shares of the business's stock in a transaction on Friday, September 19th. The shares were sold at an average price of $415.43, for a total value of $747,774.00. Following the completion of the sale, the director directly owned 5,045 shares in the company, valued at approximately $2,095,844.35. The trade was a 26.30% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, COO Michael Benkowitz sold 22,500 shares of the business's stock in a transaction on Monday, September 22nd. The stock was sold at an average price of $416.35, for a total transaction of $9,367,875.00. The disclosure for this sale can be found here. Insiders sold 187,935 shares of company stock valued at $71,728,982 in the last three months. Company insiders own 10.30% of the company's stock.

United Therapeutics Stock Up 1.1%

UTHR stock opened at $438.75 on Thursday. The company has a market capitalization of $19.79 billion, a price-to-earnings ratio of 17.13, a P/E/G ratio of 6.62 and a beta of 0.62. United Therapeutics Corporation has a 12 month low of $266.98 and a 12 month high of $442.01. The firm has a 50 day moving average of $337.52 and a two-hundred day moving average of $313.10.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last posted its earnings results on Wednesday, July 30th. The biotechnology company reported $6.41 EPS for the quarter, missing the consensus estimate of $6.80 by ($0.39). The business had revenue of $798.60 million during the quarter, compared to the consensus estimate of $802.13 million. United Therapeutics had a return on equity of 18.73% and a net margin of 40.36%.The business's revenue was up 11.7% on a year-over-year basis. During the same period in the prior year, the firm earned $5.85 earnings per share. On average, research analysts expect that United Therapeutics Corporation will post 24.48 EPS for the current fiscal year.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.

Want to see what other hedge funds are holding UTHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for United Therapeutics Corporation (NASDAQ:UTHR - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.